ERIODICTYON EXTRACT PHARMACEUTICAL COMPOSITIONS

Abstract: Methods and formulations are provided for preventing or alleviating the dryness of dermal or mucosal membranes. The compositions are formulated into aerosol sprays, delayed-release formulations, vaginal douches, creams or suppositories, all of which include eriodictyon fluid extract. The formulations may additionally contain other components such as lubricants, preservatives, bronchodilators, choleretics, antibiotics, topical anesthetics, coloring agents, emulsifiers, and the like.

Description: Eriodictyon Extract Pharmaceutical Compositions Description Technical Field The invention relates generally to methods of treatment and to pharmaceutical compositions. More particularly, the invention relates to novel aerosol, oral, and topical pharmaceutical compositions for alleviating the dryness of a substrate such as the skin or mucosal membranes of an affected patient. The active ingredient of the novel compositions includes Yerba Santa fluid extract, which is eriodictyon fluid. The invention also encompasses methods of treating dryness comprising administering an eriodictyon fluid-based composition to a substrate in order to relieve or prevent dryness. Background All mammals, and in particular humans, can suffer from dryness on particular areas of the body. The skin and mucosal membranes of the body are most often affected. With respect to mucosal membranes, the dryness is the result of the generation of an insuffi- cient quantity of mucoproteins and mucopolysaccharides on the affected area to hold fluid in contact with the cells. When insufficient moisture is present, the mucoproteins and mucopolysaccharides cannot create a sufficient barrier to irritation and infection. Accordingly, the affected individual is subjected to a higher degree of local infections with respect to the affected area, and such local infections can spread systemically. When such a systemic infection results, the consequences can be quite serious. Accordingly, it is important not only to relieve dryness in affected areas, but also to prevent the initial formation of dryness and therefore prevent the initial infections. Because the respiratory (upper and lower tracts) and gastrointestinal tracts are exposed to large amounts of foreign material, including bacteria and viruses, it is particularly important to maintain intact mucosal membranes in these areas. A number of different compositions and methods for treating various types of dryness are described within the literature. For example, U.S. Patent No. 4,232,003, issued November 4, 1980, to Posthuma et al., discloses a composition referred to as a synthetic physiological mucus which is indicated as having particular usefulness in connection in treating the dryness of vaginal tissues and as a surgical lubricant. The composition is a pituitous aqueous solution of a high molecular polyacrylamide. Such synthetic mucus compositions and methods for using such compositions to treat dryness are also disclosed within U.S. Patent No. 3,965,906, issued June 29, 1976. The general concept of imparting lubricity to a substrate such as skin, hair or mucus membranes is discussed within U.S. Patent No. 4,128,631, issued December 5, 1978. The inventors disclosed the use of a composition which includes a high molecular weight salt having a particular structural formula and molecular weight range. A more specific type of lubricating composition in the form of a vaginal suppository is disclosed within U.S. Patent No. 4,347,237, issued August 31, 1982. The suppository is solid at room temperature and melts at body temperature due to its composition which includes a variety of different types of water soluble polyoxy alkaline polyol components. As indicated above, the literature includes a number of disclosures of compositions and methods of applying those compositions to a substrate such as skin or mucus membranes in order to improve lubrication or relieve dryness. The effect is generally obtained by the application of a synthetic lubricant or a synthetic moisturizer and not by the inclusion of an active ingredient within the composition. However, U.S. Patent No. 4,184,974, issued January 22, 1980, to Leuven, discloses a lubricant composition which includes a topical biocidal agent. A similar type of composition containing such a biocidal agent is disclosed within U.S. Patent No. 4,267,168, issued May 12, 1981. The present invention is premised on the surprising discovery that the oil extracted from the Yerba Santa plant (Eriodictyon californicum; Eriodictyon glutinosum; also known as "consumptive's weed"; "bear's weed" "mountain balm" and "gum plant") is extremely effective in providing long-lasting relief of a variety of types of mild to severe dryness of dermal and mucosal membranes, particularly internal mucosal membranes, with no unpleasant side effects. The Yerba Santa plant is an evergreen shrub indigenous to the hills and mountains of California and northern Mexico, and was long used by Indians for a number of purposes. See, e.g., A.R. Hutchens, Indian Herbaloqy of North America. Ontario: Merco, 1975, at pp. 317-318. A number of references to the Yerba Santa plant teach its use as an expectorant (e.g., N. Coon, The Dictionary of Useful Plants. Em aus, Pa.: Rodale Press, (1974)), in treating colds, sore throats, catarrh, stomach aches, vomiting and diarrhea (see A.R. Hutchens, supra) , in treating hemorrhoids (D.G. Spoerke, Herbal Medications, Santa Barbara, CA: Woodbridge Press, 1980, at p. 183) , in treating diseases of the lung (Los Remedios de la Gente: A Compilation of Traditional New Mexican Herbal Medicines and Their Use, compiled by M. Moore, 1977) , and in masking the taste of quinine and other bitter medications (Spoerke, supra; see also G.E. Trease et al., Pharmacocmosy. London: Cassell & Colber, 1978, at p. 463)). In a book entitled The Herb Book, first edition, Benedict Lust Publications, New York, 1974, it is indicated that American Indians smoked or chewed the leaves as a cure for asthma. They also used the leaves as a tea for colds and for a mouthwash preparation. Drying and smoking the leaves as well as boiling the leaves in water is disclosed in other publications such as The Herb Book wherein it is indicated that Yerba Santa is an excellent expectorant, valuable for colds, chronic laryngitis, bronchitis, lung problems and asthma. A book entitled Herbal Medications, by David G. Spoerke, Jr. , published by Woodridge Press Publishing Company, Santa Barbara, California, 1980, discloses what appears to be the main use of the Yerba Santa extract which is to combine the extract with other substances in order to mask the bitter taste of a substance such as quinine. On page 183, the book specifically indicates that "The volatile oil has irritant properties that make it useful as an expectorant." The book also indicates that "The volatile oil could be irritating to the mucus membranes of the gastrointestinal tract if a large amount were taken." In the book Pharmacoqnosy (Eleventh Edition) , published by Bailliere Tindall, London, 1978, the eriodictyon fluid is described under the section entitled "Volatile Oils and Resins" and is again indicated as being a vehicle used for masking the taste of bitter and otherwise disagreeable medicines, particularly quinine. Publications discussing the Yerba Santa plant include the Coon, Hutchens, Moore, Spoerke, and Trease et al. references, cited in the preceding section, as well as V.J. Vogel, American Indian Medicine. The University of Oklahoma Press, 1970, at pp. 83, 399-400; W.H. Lewis et al., Medical Botany: Plants Affecting Man's Health. New York: John Wiley & Sons, 1977, at p. 301; P. Huson, Mastering Herbalism: A Practical Guide, New York: Stein and Day, 1974, at p. 32; B.C. Harris, The Compleat Herbal. Barre, Massachusetts: Barre Publishers, 1972, at p. 197; N. Coon, Using Plants for Healing. Hearthside Press, 1963, at p. 122; M. Grieve, A Modern Herbal, vol. 22, New York: Hafner Publishing Co., 1959, at p. 865; and V.E. Tyler et al., Pharmacognosy. Philadelphia: Lee & Febiger, 1981, at p. 148. There are known compounds possessing what is referred to as mucolytic activity on both purulent mucus and nonpurulent mucus. Perhaps the most well known is N-acetylcysteine. Because N-acetylcysteine has some undesirable properties, attempts have been made to develop new mucolytic compounds. One such group of compounds is disclosed by Maltz in U.S. Patent 4,409,138, issued October 11, 1983. This patent discloses compounds which have topical mucolytic activity in particular on secretions of the respiratory passages. The compounds are indicated as being particularly desirable in that they are not absorbed by the tissues with which they come into contact, but are able to reach the gastrointestinal tract unaltered, where they are metabolized to nontoxic products which can be completely eliminated from the body without undesirable side effects. Similar compounds are disclosed by Maltz within U.S. Patent 4,559,322 issued December 17, 1985. Other compounds have been disclosed which act as inhibitors of mucus secretion. Such compounds are disclosed within U.S. Patent 4,939,169, issued July 3, 1990, to Bundy et al. Mucolytic compounds have been known for some time as exemplified by Canadian Patent 821,525, issued August 26, 1969. This patent discloses N-acetylcysteine compositions which include a variety of excipient materials along with the active ingredient. A number of other active ingredients may be combined with the N- acetylcysteine in order to obtain a desirable pharmacological effect. Mention is made of using suitable aerosol propellants. Other mucolytic compounds which are formulated within aerosol and oral dosage forms are disclosed with European Patent Application 0,015,544, published September 17, 1990. Based on the above publications, it appears as though there is considerable art relating to possible pharmaceutical uses of eriodictyon fluid. There is also art disclosing mucolytic compounds which can be placed in the form of aerosols or oral formulations. However, the invention disclosed herein relates to specific eriodictyon fluid formulations which are applied to a substrate such as skin or mucosal membranes in order to prevent or treat dryness. The pharmaceutical formulations and methods of using such are described in detail below. Disclosure of the Invention The invention includes a method for alleviating dryness comprising administering an aerosol, oral, delayed-release, or topical composition of eriodictyon fluid extract to the dermal or mucosal tissue of a patient. The composition may also be administered in pure form, but is preferably administered in combination with other viscous excipient materials. The compositions of the invention are pharmaceutical formulations which may be administered to mucus membranes so as to coat the surfaces to which they are applied. It is an object of the invention to provide a method for treating or preventing various types of dryness of dermal and mucosal membranes, comprising topically administering, to the selected dermal or mucosal surface, a formulation containing an effective amount of eriodictyon fluid to alleviate the symptoms of dryness. It is yet another object of the invention to provide such a method wherein the composition to be administered, in addition to containing Yerba Santa extract in the form of eriodictyon fluid includes a bactericidal compound in an amount effective to kill bacteria on the area of application. It is a further object of the invention to provide such a method wherein the composition to be administered contains eriodictyon fluid, a topical anesthetic, and a preservative. It is another object of the invention to provide a composition to be topically administered, which composition contains eriodictyon fluid and a suitable excipient material which is pharmacologically compatible with the eriodictyon fluid and nonirritating to the area to which it is applied. It is another object of the invention to provide an aerosol composition for the upper and lower respiratory tracts and specifically for pulmonary administration which composition contains eriodictyon fluid, an aerosol propellant and a suitable excipient material which is pharmacologically compatible with the eriodictyon fluid and nonirritating to the pulmonary tract to which it is applied. An important object of the invention is to provide aerosol formulations which include a combination of eriodictyon fluid with another active component such as a bronchial dilator or steroidal compound normally used in connection with the treatment of respiratory tract. An important advantage of the aerosol formu¬ lations of the invention is that the eriodictyon fluid counters the drying effect normally experienced by users of aerosol formulations due to the presence of the low boiling point propellant as well as the drying effect which often results from other active ingredients such as steroidal compounds and bronchial dilators. Another important feature of the invention is that the aerosol formulations provide for better absorption of active ingredients such as bronchial dilators and steroidal compounds. It is yet another object of the invention to provide a composition in a delayed-release formulation which when administered orally will provide eriodictyon fluid to the membrane surface of the gastrointestinal tract. It is a further object of the invention to provide a method of administering an aerosol composition to a patient, wherein the aerosol composition to be administered contains eriodictyon fluid, a broncho- dilator and a preservative. It is still a further object of the invention to provide a Yerba Santa-based composition for preventing or treating various types of dryness, useful in the aforementioned methods. It is yet a further object of the invention to provide a composition for preventing or treating dryness, wherein the composition contains eriodictyon fluid and one or more excipients and additional active components selected from the group consisting of steroidal compounds, bronchial dilators, antibiotics, anti-ulcer compounds, preservative, bactericide, antivirals, antidiuretics and anesthetics. These and other objects, advantages and features of the present methods and compositions for preventing or alleviating dryness will become apparent to those persons skilled in the art upon reading the details of the composition and usage as more fully set forth below, reference being made to the accompanying general and specific composition examples forming a part hereof. Modes for Carrying Out the Invention Definitions and Overview; Before the present eriodictyon fluid-based formulations, including aerosol, delayed-release, and topical formulations, and methods for treating and preventing dryness are described, it is to be understood that this invention is not limited to the particular compositions or methods described as such compositions and methods may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims. It must be noted that as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an aerosol" includes mixtures of aerosols, reference to "an excipient" includes reference to mixtures of such excipients, reference to "the method" or "the step" includes a variety of such methods or steps of the type known to those skilled in the art, and so forth. In its broadest sense, the invention encompasses a method of preventing or treating dryness of a substrate such as skin or a mucosal membrane such as an internally located mucosal membrane by the administration of a composition of Yerba Santa fluid extract to an affected patient. By "Yerba Santa fluid extract" as used herein is meant the eriodictyon fluid which may be extracted from dried Yerba Santa leaves. One exemplary method for obtaining this Yerba Santa fluid extract is set forth in Remington's Pharmaceutical Sciences. 17th Ed., 1985, at pp. 1286 and 1516. As described in detail therein, the dried Yerba Santa plant is preferably processed in alcohol and water, followed by straining, pressing and clarification by, e.g., decantation or filtration. The eriodictyon fluid can be used in combination with a range of additional active ingredients. It must be kept in mind that the eriodictyon fluid is being administered in order to prevent or treat dryness, by mimicking the formation of mucus on an internal membrane. Accordingly, the eriodictyon fluid should not generally be formulated with mucolytic compounds which break up mucus or compounds which inhibit mucus excretion. In addition to considering the pharmacological affect of any active ingredients combined with the eriodictyon fluid, those skilled in the art will make note of the physical characteristics of such active ingredients as taken alone, or in combination with eriodictyon fluid so as to choose ingredients which can be formulated into desirable formulations, such as sprays or aerosols which can be efficiently delivered to the respiratory tract. In a preferred embodiment, the composition is administered as a topical composition of eriodictyon fluid extract containing one or more excipients. The composition will preferably contain in the range of 0.25 wt.% to 10 wt.%, more preferably 0.5 wt.% to 5.0 wt.%, and most preferably about 1.25 wt.% eriodictyon fluid extract. Depending on the area to which the composition is applied the composition will also contain one or more additional active ingredients such as bactericides, antivirals, and anesthetics, in total comprising about 1.0 wt.% to 30 wt.%, more preferably 10 wt.% to 20 wt.%, with the amount varying with the class and specific type of ingredient used. Topical compositions are preferably administered as a viscous cream, which is readily prepared by admixing the Yerba Santa fluid extract with selected excipient components. Such compositions may also be prepared as douches or suppositories, with the preferred components and the preferred relative compositions by weight described herein. in another preferred embodiment, an aerosol formulation of eriodictyon fluid extract is administered to the upper and lower respiratory tracts by spraying and inhaling the formulation. The composition will preferably contain in the range of 0.25 wt.% to 10 wt.%, more preferably 0.5 wt.% to 5.0 wt.%, and most preferably about 1.25 wt.% eriodictyon fluid extract. Depending on the area to which the composition is applied the aerosol composition will also contain one or more additional active ingredients such as antiasthma compounds, steroids, anti-inflammatory agents, bronchial dilators, antihistamines and antibiotics, in total comprising about 0.1 wt.% to 30 wt.%, more preferably 10 wt.% to 20 wt.%, with the amount varying with the class and specific type of ingredient used. Specific examples of compounds in each of these general classes are given in the Physicians Desk Reference. Oradell, N.J. : Medical Economics Co., Inc. (1988). Additional therapeutic agents which might be combined with the eriodictyon fluid (in similar amounts to those indicated above) in an aerosol formulation include vasoconstrictors, vasodilators, sulfa drugs, enzymes, surfactants and antiseptics. Aerosol formulations have been used for some time to treat various abnormalities of the respiratory tract. Aerosol formulations are effective in that they provide the active ingredient directly to the tissue which needs to be treated. However, many of the active ingredients which are brought into the contact with the respiratory tract can have a drying effect on the mucus membranes of the respiratory tract. Further, aerosol formulations are generally comprised of a large amount of a low boiling point hydrocarbon or low boiling point fluorocarbon which can dissolve and/or dry the mucus on the internal membranes of the respiratory tract. Therefore, although such formulations can be effective in obtaining a particular result such as bronchial dilation, the same formulations can have an undesirable drying effect on the mucus membranes. The present invention provides a means for counterbalancing the mucus drying or mucus dissolving effect caused by some active ingredients and/or propellants. By including the eriodictyon fluid with the propellants and/or other active ingredients, it is possible to remoisten the membranes and/or maintain the mucus membranes intact. The eriodictyon fluid can be formulated by itself with a propellant and administered after the administration of another compound or formulated together with another active ingredient so that both compositions can be applied simultaneously. The precise dose of eriodictyon fluid to be administered in an aerosol formulation varies depending on a number of factors. Most importantly, the need for the eriodictyon fluid will vary depending on the need of the particular patient to prevent and/or alleviate dryness of the respiratory tract. Some patients have excess mucus and should not be prescribed eriodictyon fluid. Other patients suffer from severe loss of fluid on many surfaces and would require a higher dosage of eriodictyon fluid and repeated administration of the aerosol formulation. Precise doses will depend on other factors as well, such as the responsiveness of the patient. Dosing will generally be in similar amounts to the dosing of the other active ingredient such as the bronchial dilator being administered. Precise amounts will be determined by the care giver based on patient responsiveness. In still another embodiment of the invention, an oral formulation of eriodictyon fluid extract is provided to coat the stomach walls. As with the other embodiments of the invention, such a formulation mimics mucus formation on the stomach wall. In accordance with another embodiment of the invention, a delayed-release formulation of eriodictyon fluid extract is administered to the gastrointestinal tract. The delayed-release formulations of the invention include conventional delayed-release formulations which incorporate the eriodictyon fluid extract therein. When the delayed-release formulations are administered orally the active ingredient (i.e., the eriodictyon fluid extract) is not released in the stomach due to the composition of the delayed-release formulation. After the formulation moves into the intestines, release of the eriodictyon fluid begins. The fluid is thus administered along the intestines where it comes into contact with the internal surfaces of the intestine walls and thereby alleviates dryness. A typical delayed-release formulation includes about 10 to 200 mg. of eriodictyon fluid in a delayed-release capsule, caplet or tablet. A typical dose involves the oral administration of one to four tablets. However, the specific amount of eriodictyon fluid administered and the frequency of the administration will again be variable, to be determined by the care giver depending on the condition of the patient and responsiveness to treatment with eriodictyon fluid. In order to provide for a uniform distribution of active ingredient in a formulation it may be desirable to include a dissolution-assisting agent. Examples of such agents include nonionic surface active agents, such as polyoxyethylenesorbitan monooleate, polyoxyethyleneoxystearic acid triglyceride, polyethylene glycol, etc. It is preferred that the formulations of the invention also contain a preservative which is added to increase shelf life. Preferred preservative compounds include quaternary ammonium bacteriostats such as benzalkonium chloride, present in an amount ranging from about 0.25 wt.% to about 5.0 wt.%, preferably about 0.5 wt.%. Incorporation of any of phenyl mercuric acetate, thimerosal, or benzyl alcohol into the present composition also serves to retard bacterial growth in the composition. A thickening agent may be.added, such as, for example, polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, etc. As an antiseptic, those conventionally used may be mentioned, for example, benzalconium chloride, cetylpyridinium chloride, chlorobutanol, methylparaben, propylparaben, etc. A chelating agent, such as sodium ethylenediaminetetraacetate (EDTA-Na) , may be used. The formulations of the invention may include a pH buffer. The pH of the formulations of this inven¬ tion is preferred to be 6.5-8.5, particularly about 7.5. Specific examples of formulation ingredients other than those already referred to and preferred formulation amounts will be exemplified herein below. The various types of formulations within the scope of the present invention will now be described in detail. Topical and Transmucosal Formulations; In one embodiment of the invention, a liquid composition is provided in a form suitable for use as a vaginal douche. In such a composition the eriodictyon fluid is present in an aqueous carrier (largely pure water) with a small amount of acetic acid to adjust the pH to that which is equal to the vagina (about 5.0). Such a liquid composition is generally comprised of about 90-99% water and about 1-10% of the eriodictyon fluid of the invention. After providing for the essential components of the water and eriodictyon fluid, the pH of the composition is adjusted by adding acetic acid in an amount which will decrease the pH of the final solution to somewhere in the range of 4.0 to 6.0, and more preferably about 5.0. The composition preferably includes a preservative such as sodium benzoate, which is generally present in relatively small amounts such as in the range of 0.1 wt.% to about 1 wt.%, more preferably about 0.25 wt.%. Another particularly preferred embodiment of the present invention is a liquid composition in the form of a nasal decongestant spray. Such a composition is largely comprised of water. It may include 90-99% water and 1-10% of eriodictyon fluid. Such a nasal spray composition preferably includes a component which aids in nasal decongestion, such as ephedrin sulfate in an amount of 0.05 to 1 wt.%, and more preferably about 0.25 wt.%. In order to provide for additional lubrication, it is often preferable to include glycerine in an amount of 1-5 wt.%, more preferably about 3 wt.%. In that the composition is to be used for nasal administration, the saline content of the solution is adjusted so that its saline content is approximately equal to that of the nasal environment to which it will be applied. Further, the pH of the composition is adjusted to a pH compatible with nasal membranes, which can be accomplished by buffers known to those skilled in the art. In a particularly preferred embodiment of the nasal spray, the eriodictyon fluid is present in an amount of about 1.5%, ephedrin sulfate 0.25%, glycerine 3%, sodium chloride 0.80%, EDTA and benzalkonium chloride, buffered to nasal pH. The liquid nasal composition of the invention provides a nasal mucosal decongestant and lubricant which is useful in treating allergic rhinitis, vasomotor rhinitis, rhinitis medicamentosa, rhinitis sicca, sinusitis, and atrophic rhinitis. The liquid nasal composition of the invention is applied by spraying the composition into the nostrils once or twice while tilting the head back. The administration may be repeated two or three times a day or as directed in order to obtain the desired relief of dryness and/or decongestion of the nasal passages. One important embodiment of the invention is a moisturizing lubricant in the form of a suppository, which lubricant is designed specifically for the human vagina. An aspect of this invention relates to a precoital lubricant in suppository form. Still another aspect of this invention relates to a method for lubricating the human vagina by insertion of a solid suppository which melts to form a lubricant at human body temperature. When insertion of any material into a human body canal (particularly the vagina or anus) is desirable, suppositories have advantages and are often preferred by patients, doctors, and other users. The suppository art is a highly developed one, particu¬ larly with respect to suppositories which provide a matrix for releasing some medicament. Such supposi- tories can be made lubricious; see, for example, U.S. Patent No. 3,776,001 (Hanke) , issued December 4, 1973. Medicators, tampons, and the like have also been made lubricious, at least on their surfaces. Suppositories of this invention are solid at normal ambient temperatures but melt at human body temperature to form a substantially homogeneous liquid having the appearance of a single liquid phase, even though a glyceride of an aliphatic carboxylic acid is distributed through this homogeneous liquid. In either the liquid or solid state, suppositories of this invention could include the following nonactive components: (a) a continuous phase comprising a polyoxyalkylene polyol component consisting essentially of polyethylene glycols having a molecular weight within the range of 400 to 5,000, so that this component will have a melting range low enough for the purposes of this invention; (b) about 10-60 parts per 100 parts by weight of the aforementioned polyol component (and typically 10-30% by weight of the suppository) , of a nonionic surfactant having an HLB value greater than 12 (typically this surfactant dissolves in the polyol component) ; and (c) about 10-40 parts per hundred, based on the weight of the polyol component, of a glyceride (preferably a triglyceride) of an aliphatic carboxylic acid, which glyceride is uniformly distributed throughout the continuous phase with the aid of the nonionic surfactant. The human vagina can be precoitally lubricated with a suppository of this invention by inserting the solid suppository and permitting it to melt within the vaginal canal prior to coitus. The melting is generally complete within a very few minutes. If desired, the insertion can take place up to a few hours before coitus. Suppositories of this invention are made by melting the polyethylene glycols at a moderately elevated temperature, thereby obtaining a homogeneous melt. The preferred nonionic surfactant (including surfactant combinations) can be dissolved in the melt. The resulting hot mixture is a suitable medium for distributing the glyceride, which is the primary lubricating substance. When a suitable blend has been for ed, it can be cast into the form of suppositories using molds or a suppository packaging material that serves as both mold and package. The components of suppositories, the relative amounts of those components, and methods of making such are described in detail in U.S. Patent No. 4,347,237. It is also pointed out that other U.S. patents are cited in 4,347,237 to describe the suppository art in general. A variety of different excipients could be used in combination with eriodictyon fluid to form a useful suppository of this invention. As alluded to above, the eriodictyon fluid component promotes the release of natural moisture from any substrate it is applied to such as dermal and mucus membrane substrates. However, the topical formulations of the invention which include suppositories are preferably formulated so that for example, even in the absence of natural vaginal moisture, a fully or partially melted suppository or vaginal insert of this invention has lubricating properties. The combination of ingredients of this invention preferably allows the melted lubricating substance to become miscible with the vaginal moisture present even in small amounts. As the insert or suppository melts and mixes with any vaginal moisture, it spreads readily throughout the vagina. In addition, the lubricity of the invention is not reduced due to evaporation of moisture during coitus. Topical and suppository compositions of the invention can be formulated by dispersing small amounts (i% to 15% by weight) of eriodictyon fluid in one or more (preferably a blend) of polyoxyethylene or polyethylene glycols. These glycols contain an oxyethylene chain with an extraordinary compatibility with water and with a hydroscopicity of at least 0.1%, preferably at least 1% of glycerin. Because these polyethylene glycols make up such a large proportion of the lubricating suppository, it is preferred that a single such glycol (if used alone) or any combination of such glycols be solid at normal ambient temperatures (20°-25°C) and preferably at moderately elevated temperatures which may inadvertently be reached during storage, e.g., 30° or 35°C. On the other hand, it is desirable that the glycol component be capable of melting at temperatures close to human body temperature (e.g., 37°C) . The melting point of the glycol component can of course be depressed by blending into it compatible liquids or low-melting solids. Nevertheless, it is preferable that, in the absence of such liquids or low-melting solids, the glycol component have a melting point or melting range low enough to insure the formation of a clear molten liquid at less than about 75°C, more preferably at less than about 55° or 60°C. Among the low-melting solids and liquids which can provide the aforementioned melting point depressant effect are low molecular weight polyoxyethylene glycols which are available in molecular weights well below 1,000 (equivalent weights well below 500). It is preferred however to keep the molecular weight of the lowest-melting glycol above about 400. A polyethylene glycol having an average molecular weight of about 500 could be a solid at 20°C, but may have the consistency of low-melting petrolatum. The particular glycol including its amount and molecular weight can be determined by those skilled in the art depending on the end results desired. Suppositories will typically be shaped solids containing the resinous Yerba Santa fluid extract in a base which slowly melts at body temperature. Prepa¬ ration of suppository forms is well known in the art, and is described, for example, in Remington's Pharmaceutical Sciences. 17th edition, cited supra, at pages 1580-1584. Typically, the Yerba Santa extract is mixed with other optional compounds as described above. The resulting mixture is shaped and/or compressed into the desired form. The pH of this product is preferably adjusted to that normally encountered in the mucus secretions for which the product is being substituted. The excipients should be stable in the useful pH range of about 3-10. For vaginal mucus substitution, the pH is adjusted to about 5-8, normally to about 5, with a suitable acidic reagent or the like that has no significant epidermal or mucosal toxicity, such as citric acid or similar weak organic acids. Natural vaginal mucus has a normal pH of about 5, but this pH does vary a great deal such that the pH range of about 5-8 for the synthetic mucus is acceptable. The excipient materials for topical compositions of the invention may include glycol, glyceride, lubricant, and surfactant components further modified with a lower aliphatic monomeric hydrophilic polyol which will dissolve in the glycol phase. A preferred monomeric polyol is glycerin. Pigments, fillers, extenders, preservatives, and antioxidants can also be included in the composition, but it is ordinarily preferred to avoid the use of any filler, extender, or pigment which will leave a visible solid residue. For antioxidant or preservative effects, various FDA-approved compounds are suitable, including the conventional alkylated hydroxy aromatic compounds such as BHT (butylated hydroxytoluene) or BHA (butylated hydroxyanisole) . Aerosol Formulations: Another particularly preferred embodiment of the invention is a pressurized aerosol formulation composition in a form suitable for pulmonary administration carried out by simultaneously spraying and inhaling. In such a composition the eriodictyon fluid is present in a low boiling point carrier and perhaps water. Detailed information regarding the formulation of aerosols may be found in Remington's Pharmaceutical Sciences f 17th Edition, Mack Publishing Company, 1985, Chapter 93, pp. 1662-1677, and used in connection with the present invention to provide eriodictyon fluid- containing aerosols. Although a number of aerosol systems are possible, the simplest provides a solution or suspension of active ingredients in a liquid propellant such as a low boiling point compound such as a short (1-4C) chain hydrocarbon or fluorinated hydrocarbon or a mixture of such propellants in combination with a solvent. In such a system, both the liquid and vapor phases are present. When the valve on a container of such a formulation is depressed, liquid propellant containing dissolved active ingredients and other solvents is released. Depending upon the nature of the propellants used, the quantity of propellant present and the valve mechanism, a fine mist or wet spray is produced due to the large expansion of the propellant at room temperature and atmospheric pressure. Such a system can be used to formulate aerosols for inhalation through the mouth into the respiratory tract or nasal application into the respiratory tract. A variety of fluorocarbon propellants are used although dichlorofluoromethane and dichloro- tetrafluoroethane are commonly used in oral aerosols. In addition to fluorocarbon propellants, various low boiling point hydrocarbon propellants or compressed gases may be used to provide aerosol formulations. Some typical hydrocarbon propellants include propane, isobutane and n-butane. In addition, ethers can be used such as dimethy1ether. It is pointed out that the present invention is attempting to obtain a coating on an internal mucosal membrane in the respiratory tract, particularly pulmonary tissues. Since it is desirable to coat the membrane and not have the eriodictyon fluid within the spray absorbed into the membrane, it is desirable to provide a relatively wet or coarse spray. This can be achieved by decreasing the amount of the low-boiling propellants and increasing the ratio of the eriodictyon fluid and/or solvents (e.g. , water) which might be used in combination with this fluid. The eriodictyon fluid may be present in an amount in the range of about 20- 75% with the propellant being present in an amount in the range of about 25-80%. With such formulations, particles produced generally range in the size of from 50 μm to 200 μm. Such a liquid aerosol composition is generally comprised of about 20-99% (by weight) low boiling point propellant and about 1-80% (by weight) eriodictyon fluid extract. After providing for the essential components, i.e., propellant and eriodictyon fluid extract, the pH of the composition is adjusted by adding pH buffers of the type generally known to those skilled in the art. The aerosol formulations of the invention are administered by spraying the formulation into the mouth and/or nose and inhaling at the same time. Accordingly, the sprayed formulations enter the bronchial passages and eventually the lungs. It is preferred to adjust the saline content of the aerosol formulation so as to closely match the bronchial and pulmonary environment to which the formulation is applied. This can be done by adding aqueous saline solutions of the type generally known to those skilled in the art. Adjustments in saline content and pH are preferably carried out so as to match as closely as possible the environment which the formulation is being applied to so as to reduce as much as possible any irritation which might be created by the formulations. The aerosol formulation preferably includes a preservative such as sodium benzoate, which is generally present in relatively small amounts such as in the range of 0.1 wt.% to about 1 wt.%, more preferably about 0.25 wt.%. The eriodictyon fluid component coats and protects an area and allows for the release of natural moisture from any substrate it is applied to such as mucus membrane substrates in the respiratory and gastrointestinal tracts. The excipient materials for aerosol formulations of the invention may include pigments, fillers, extenders, preservatives, and antioxidants can also be included in the composition, but it is ordinarily preferred to avoid the use of any filler, extender, or pigment which will leave a visible solid residue. For antioxidant or preservative effects, various FDA-approved compounds are suitable, including the conventional alkylated hydroxy aromatic compounds such as BHT (butylated hydroxytoluene) or BHA (butylated hydroxyanisole) . Oral Formulations: Oral formulations containing eriodictyon fluid extract, e.g., to coat the stomach walls, can be in the form of a solid, semi-solid or liquid dosage form, such as, for example, tablets, suppositories, pills. capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions will include an amount of eriodictyon fluid extract sufficient to produce the desired result in the individual undergoing treatment, and may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, or the like. For solid compositions, it is preferred to use conventional nontoxic solid excipients such as, for example, pharmaceutical grades of mannitol, lactose, starch, or the like. For liquid compositions, preparation may be effected by dissolving, suspending or dispersing eriodictyon fluid extract and, optionally, additional active compounds or pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, or the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanola ine sodium acetate, triethanolamine oleate, etc. Actual method of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences. Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975, cited earlier herein. The composition or formulation to be administered will, in any event, for purposes of coating the stomach walls, contain an effective amount of eriodictyon fluid extract, i.e., an amount effective to achieve the desired therapeutic effect in the subject being treated. If desired, oral formulations may be made such that delayed release is achieved, as described in the next section. Delaved-Release Formulations: in order to provide for the administration of the eriodictyon fluid to the mucosal membranes of the intestines, it is necessary to formulate the fluid into a delayed-release formulation. A variety of sustained- release/delayed-release drug delivery systems are disclosed with the above-cited Remington's Pharmaceutical Sciences. Delayed-release formulations of the invention can be in the form of tablets, capsules, caplets and other variations (e.g., transdermal) as discussed within Remington's and which will be known to those of ordinary skill in the art of providing for delayed-release oral and other types of formulations. In connection with the present invention, it is desirable to formulate the eriodictyon fluid into a delayed-release oral formulation such as tablets, capsules and microcapsules which will pass through the stomach and upper intestines before they begin deterioration. Once in the lower intestines, deterioration of the polymer coating begins allowing for a release of the eriodictyon fluid contained therein. Preferably, the deterioration of the polymers in the formulation occurs at different times so that the eriodictyon fluid can be released over the entire length or a relatively substantial length of the lower intestines and thus provide the eriodictyon fluid to a large surface area, i.e., a major proportion of the surface area of the lower intestines. The delayed-release formulations of the invention may include eriodictyon fluid extract formulated by itself (with the appropriate excipients) , i.e., without any additional active agents, to allow for the delayed-release results desired. However, formulations of the invention may include other active ingredients such as choleretics, e.g., alibendol, dehydrocholic acid, hymecromone, piprozolin, sincalide and tocamphyl. These pharmaceuticals may be administered to patients suffering from various forms of intestinal abnormalities. Other similar pharmaceuticals will be known to those skilled in the art and are disclosed and described within the above-cited Physicians Desk Reference. The delayed-release formulations may include excipient materials such as a number of substances of synthetic origin including styrene and butadiene-styrene polymers, isobutylene-isoprene copolymers, paraffin, petroleum wax, polyethylene, polyisobutylene, polyvinylacetate, etc., plasticizers or softeners such as lanolin, stearic acid, sodium stearate, potassium stearate, glycerol triacetate, glycerine, and the like. In general, it is not necessary to particularly adjust the pH of the delayed-release formulation. What is necessary is that the formulation be adjusted so that it is responsive to the pH it is exposed to and that its responsiveness provides the objects of the invention. More particularly, the delayed-release formulation is administered orally and comes into contact with the extremely low pH of the stomach. At this point (in the stomach) , the formulation should not be dissolved so as to release the eriodictyon fluid contained therein. It is desirable if none of the eriodictyon fluid is released within the stomach and that essentially all of the eriodictyon fluid remains within the formulation intact until the formulation passes out of the stomach. When material passes out of the stomach into the intestines, it comes into contact with an alkaline pH environment. Accordingly, the delayed-release formulation should be formulated so that after exposure to acid, it becomes broken down when it is exposed to alkaline excretions within the intestines. Preferably, the release of the eriodictyon fluid in the intestines is somewhat gradual so that the eriodictyon fluid is spread over a substantial portion of the intestines and is therefore allowed to coat a substantial portion of the mucus membranes substrates lining within the intestines. Those skilled in the art are capable of formulating delayed-release formulations so as to obtain these objects. Formulation Additives: Small amounts of a variety of different biocidal agents can be included in the formulations of the invention. They may be added to kill bacteria or viruses or both on the substrate to which the inventive formulations are applied. Further, they may be added to prevent or hinder bacterial growth in the formulation during storage. The inclusion of silver ions are known to have such an effect and can be included in amounts of 10 to 500 ppm by adding silver nitrate to the composition. Such biocidals are described in U.S. patent 4,267,168, issued May 12, 1981. It is preferred that the composition contain one or more preservatives, typically an antioxidant present in an amount effective to retard oxidation and/or inactivate the fluid extract. As with other additives, both active and inactive, the selection will be readily made by one skilled in the art. Examples of suitable preservatives include ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, potassium or sodium sorbate, sodium bisulfite, sodium metabisulfite, sorbic acid, sulfur dioxide, and sodium or potassium benzoate. A particularly preferred preservative for use in formulations of the invention is sodium benzoate. Compositions of the invention which are to be applied to a dermal substrate often contain emollients such as stearic acid, glycerol monostearate, mineral oil, glycerine, sesame oil, beeswax, lauryl, myristyl, cetyl or stearyl alcohols, lanolin, lecithin, sterols, isopropylmyristate, and as well any other recognized emollients. Emollients are typically used in the present invention at levels of from about 1% to about 50% by weight. Astringents and antiseptics may also be incorporated into the compositions of the present invention. A preferred astringent material is zinc phenolsulfonate. The foregoing material exhibits not only astringent but also antiseptic qualities. Hu ectants such as propylene glycol are also desirable ingredients for inclusion in personal care products to prevent drying of the skin. Allantoin is included in such compositions for its purported soothing and healing effects upon injured skin. Other components which may, if desired, be incorporated into the present composition include coloring agents, which may be either natural or synthetic, diluting agents, emulsifying agents, excipients, pH buffering agents, and the like. Suitable colorants include dyes that are generally suitable for food, drug and cosmetic applications, i.e., those known as "F.D. & C." dyes. Where the Yerba Santa composition is in an aerosol form, acceptable dyes should be soluble in the propellant. Where the composition is in aqueous form, dyes should be water-soluble. Illustrative examples include the disodium salt of 5,5-indigotin-disulfonic acid ("F.D. & C. Blue No. 2") and the monosodium salt of 4-[4-N-ethyl- p-sulfo-benzylamino)-diphenylmethylene]-[l-(N-ethyl-N- p-sulfonium-benzyl)-2,5-cyclohexadienimine ("F.D. & C. Green No. 1") . Reference may be had to the Kirk-Othmer Encyclopedia of Chemical Technology, 3rd Ed. , in Volume 6, for further F.D.& C. colorants and corresponding chemical structures. Waxes, including low melting point natural and synthetic waxes, petroleum waxes, paraffin waxes and microcrystalline waxes may also be incorporated into the topical and delayed-release formulation. The amount of Yerba Santa extract administered will, of course, be dependent on the subject being treated, the severity of the dryness, and the judgment of the prescribing health care professional. However, an effective dosage regimen will typically be 1-2 aerosol sprays of one second duration, or 1-2 tsp of a topical composition containing 0.25 wt.% to 10 wt.% Yerba Santa fluid extract. It is preferred that a sufficient dose be provided so that the extract be retained in contact with the dermal or mucosal membrane being treated for a time sufficient to allow the Yerba Santa fluid extract to fully coat and remain on the membrane for a substantial period of time. The coating should remain in place for sufficient time to allow the natural membrane to replace itself. Reapplication of a formulation of the invention to the dry area may be and often is required in order to obtain the desired results. EXAMPLES The following examples are provided so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make the formulations and perform the methods of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to insure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviation should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in degrees C, and pressure is at or near atmospheric. Example 1 Ingredients Quantity Excipient (carrier) 1.0-99.0 wt.% -Yerba Santa Fluid Extract * 99-1.0 wt.% Other Components 0-9.0 wt.% Dried eriodictyon can be obtained from Meer Corporation, North Bergen, New Jersey; it can be used to prepare the fluid extract in a manner substantially as described in Remington's Pharmaceutical Sciences, 17th Ed., cited supra, on pages 1286 and 1516. After preparation of the fluid extract, the above ingredients can be mixed to give a formulation of Yerba Santa fluid extract. Example 2 Ingredients Quantity Excipient (lubricant cream) 98.50 wt.% Yerba Santa Fluid Extract * 1.25 wt.% Preservative 0.25 wt.% One to two teaspoons of the above topical composition can be administered as needed to obtain relief from or prevent dryness. Example 3 Ingredients Quantity Excipient (aqueous) 90.0-98.50 wt.% Yerba Santa Fluid Extract * 10.0-1.50 wt.% The aqueous excipient will preferably include pure water and acetic acid in sufficient amount to adjust the pH to about 5.0. The excipient also preferably includes a preservative such as sodium benzoate in an amount of about 0.1 to 0.5 wt.%. The solution can be used as a vaginal douche. Example 4 Ingredients Quantity Lubricant/Moisturizer 98.50 wt.% Yerba Santa Fluid Extract * 1.25 wt.% Sodium Benzoate 0.25 wt.% This composition is in the form of a cream which can be applied to any dry area. Example 5 Ingredients Quantity Polyoxyalkylenepolyol 98.75 wt.% Yerba Santa Fluid Extract * 1.00 wt.% Sodium Benzoate 0.25 wt.% This composition is a solid suppository at room temperature and melts at body temperature. Example 6 Ingredients Quantity Excipient 96.75 wt.% Yerba Santa Fluid Extract" 1.00 wt.% Sodium Benzoate 0.25 wt.% Biocidal Agent 2.0 Wt.% Example 7 Ingredients Quantity Excipient (aqueous) 95.75 wt.% Yerba Santa Fluid Extract" 3.00 wt.% Sodium Benzoate 0.25 wt.% Acetic acid 1.0 Wt.% Example 8 Ingredients Quantity Excipient (topical cream) 97.50 wt.% Yerba Santa Fluid Extract * 1.25 wt.% Sodium Benzoate 0.25 wt.% Antiviral Agent 1.0 wt.% Example 9 Ingredients Quantity Synthetic Mucus 90.0-99.0 wt.% Yerba Santa Fluid Extract" 1.0-10.0 wt.% Preservative 0.25 Wt.% Example 10 Ingredients Quantity Polyoxyalkylenepolyal 50.0 wt.% Yerba Santa Fluid Extract * 1.25 wt.% Sodium Benzoate 0.25 wt.% Glycerine 48.0 wt.% Bacteriocidal Agent 0.5 Wt.% Example 11 Ingredients Quantity Water (0.0-99.C Eriodictyon Fluid 1.0-10.0 wt.% pH Buffer 0.0-9.0 Wt.% The composition could, of course, include preservatives. The pH of the composition is adjusted to match the pH of the mucosal tissues to which the composition is applied. Example 12 Ingredients Quantity Water 90.0-99.0 wt.% Eriodictyon Fluid 1.0-10.0 wt.% pH Buffer 0.0-9.0 wt.% Sodium Chloride 0.01-5.0 wt. • 6 The above composition is most useful in connection with nasal sprays. The composition may further include other active components such as decongestants. The sodium chloride is added in an amount to adjust to the saline composition of normal nasal mucosal tissues, as is the pH of the composition. Example 13 Ingredients Quantity Water/Aerosol Propellant 80.00 wt.% Yerba Santa Fluid Extract * 19.75 wt.% Preservative 0.25 wt.% One to two sprays of one second duration of the above aerosol composition can be administered as needed to obtain relief from or prevent dryness of the pulmonary tract. Example 14 Ingredients Quantity Excipient (fluorocarbon/solvent) 20-30 wt.% Yerba Santa Fluid Extract * 80-70 wt.% The excipient also preferably includes a preservative such as sodium benzoate in an amount of about 0.1 to Example 15 Ingredients Quantity Aerosol Propellant/Water 20 wt.% Yerba Santa Fluid Extract * 79.75 wt.% Sodium Benzoate 0.25 wt.% This composition is in the form of an aerosol which can be applied to the respiratory tract so that they reach deep internal areas of the pulmonary tract. Example 16 Ingredients Quantity Polystyrene Polymer 98.75 wt.% Yerba Santa Fluid Extract * 1.00 wt.% Sodium Benzoate 0.25 wt.% This composition is a solid tablet for delay release in the intestines after oral administration. Example 17 Ingredients Quantity Fluorocarbon Propellant/Water 96.75 wt.% Yerba Santa Fluid Extract * 1.00 Wt.% Sodium Benzoate 0.25 wt.% Bronchial Dilator 2.0 Wt.% Example 18 Ingredients Quantity n-Butane/Water 95.75 wt.% Yerba Santa Fluid Extract" 3.00 Wt.% Sodium Benzoate 0.25 wt.% Theophylline 1.0 Wt.% Example 19 Ingredients Quantity Propane/Water 97.50 Wt.% Yerba Santa Fluid Extract" 1.25 Wt.% Sodium Benzoate 0.25 wt.% Antibiotic 1.0 Wt.% Example 20 Ingredients Quantity Polypropylene 50.0-99.0 wt. Yerba Santa Fluid Extract" 1.0-50.0 wt. Preservative 0.25 Wt.% Example 21 Ingredients Quantity Polystyrene 40.0 wt.% Polypropylene 47.5 wt.% Yerba Santa Fluid Extract 11.25 wt.% Sodium Benzoate 0.25 wt.% Choleretic Agent 1.0 wt.% Example 22 Ingredients Quantity Dimethylether/Water 20% wt.% Eriodictyon Fluid 79% wt.% steroidal 1.0 wt.% The above general example could, of course, include preservatives. The pH of the composition is adjusted to match the pH of the mucosal tissues of the respiratory tract the composition is applied. Example 23 Ingredients Quantity Water/propellant 20-80 wt.% Eriodictyon Fluid 80-20 wt.% pH Buffer 0.0-9.0 Wt.% Sodium Chloride 0.01-5.0 Wt.% The above composition may further include other active components such as decongestants. The sodium chloride is added in an amount to adjust to the saline composition of normal respiratory tract mucosal tissues, as is the pH of the composition. While the present invention has been described with reference to the specific embodiments including methods and formulations for treating dryness, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular substrate surface to be treated, excipient, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

Claims: Claims 1. A method of imparting moisture to a substrate selected from the group consisting of skin and mucus membranes, comprising the steps of: contacting the substrate with eriodictyon fluid extract in an amount sufficient to achieve an acceptable degree of moisture on the contacted tissue; and allowing the eriodictyon fluid extract to remain in contact with and coat the substrate for sufficient time and in sufficient amount so as to cause the substrate to have moisture imparted thereto. 2. The method as claimed in claim 2, wherein the substrate is vaginal, nasal, sinus, ocular, anal, lip or urethral tissue. 3. A topical composition, comprising: a pharmaceutically effective amount of eriodictyon fluid extract; and a viscous excipient material pharmaceutically compatible with the eriodictyon fluid extract and nonirritating to a mucus membrane, the eriodictyon fluid extract being dispersed throughout the excipient material. 4. The topical composition as claimed in claim 3, further comprising: a pharmaceutically acceptable preservative present in an amount effective to retard oxidation of the composition and retard bacterial growth therein. 5. An aqueous vaginal douche composition, comprising: a pharmaceutically effective amount of eriodictyon fluid extract; and aqueous excipient material pharmaceutically compatible with the eriodictyon fluid extract and nonirritating to vaginal tissues, the eriodictyon fluid extract being dispersed throughout the excipient material. 6. The aqueous vaginal douche composition as claimed in claim 5, further comprising: a pharmaceutically acceptable preservative present in an amount effective to retard oxidation of the composition and retard bacterial growth therein. 7. The aqueous vaginal douche composition as claimed in claim 5, wherein the aqueous excipient is comprised of water and acetic acid and the pH of the composition is in the range of about 4.0 to about 6.0. 8. An aqueous nasal composition, comprising: a pharmaceutically effective amount of eriodictyon fluid extract; and aqueous excipient material pharmaceutically compatible with the eriodictyon fluid extract and nonirritating to nasal mucosal membranes, the eriodictyon fluid extract being dispersed throughout the excipient material, the excipient comprising pure water, sodium chloride, and a pH buffer, wherein the sodium chloride and pH buffer are present in sufficient amounts so as to provide for a composition with a saline content and pH compatible with nasal mucosal membranes. 9. The aqueous nasal composition as claimed in claim 8 further comprising: a nasal decongestant. 10. The aqueous nasal composition as claimed in claim 8, wherein the eriodictyon fluid is present in an amount in the range of about 1.0 wt.% to about 10.0 wt.%. 11. A method of imparting moisture to mucosal membrane substrates in the upper and lower respiratory tracts, comprising the steps of: contacting the substrates with eriodictyon fluid extract in an amount sufficient to achieve an acceptable degree of moisture on the substrate; and allowing the eriodictyon fluid extract to remain in contact with and coat the substrates for sufficient time and in sufficient amount so as to cause the substrates in the upper and lower respiratory tract to have moisture imparted thereto. 12. The method as claimed in claim 11, wherein the contacting is carried out by administering an aerosol formulation. 13. An aerosol composition, comprising: a pharmaceutically effective amount of eriodictyon fluid extract; and a low boiling point propellant material pharmaceutically compatible with the eriodictyon fluid extract and nonirritating to a mucus membrane of the upper and lower respiratory tract, the eriodictyon fluid extract being dispersed throughout the propellant material. 14. The aerosol composition as claimed in claim 13, wherein the active component is a bronchial dilator or steroidal compound. 15. A delayed-release formulation, comprising: a pharmaceutically effective amount of eriodictyon fluid extract; and excipient material pharmaceutically compatible with the eriodictyon fluid extract and nonirritating to tissue of the gastrointestinal tract, the eriodictyon fluid extract being dispersed throughout the excipient material in such a manner so as to allow release of eriodictyon fluid extract from the formulation in the intestines after oral administration and prevent release of the eriodictyon fluid in the upper gastrointestinal tract. 16. The delayed-release formulation as claimed in claim 15, further comprising: a pharmaceutically acceptable choleretic compound. 17. A pressurized aerosol formulation comprising: a pharmaceutically effective amount of eriodictyon fluid extract; and a low boiling point propellant pharmaceutically compatible with the eriodictyon fluid extract and nonirritating to respiratory tract mucus membranes, the eriodictyon fluid extract being dispersed throughout the propellant which is comprised of a low boiling point hydrocarbon in combination with a pH buffer in an amount sufficient to provide the composition with a pH in the range of about 6.5 to about 7.5 and a saline solution in a amount so as to match the saline content of tissues of the respiratory tract. 18. A method for imparting moisture to and thereby coating the stomach walls, comprising orally administering to an individual in need of such treatment a formulation containing an effective amount of eriodictyon fluid extract. 19. A method for imparting moisture to mucosal membrane substrates in the gastrointestinal tract, comprising the steps of: contacting the substrates with eriodictyon fluid extract in an amount sufficient to achieve an acceptable degree of moisture on the substrates; and allowing the eriodictyon fluid extract to remain in contact with and coat the substrates for sufficient time and in sufficient amount so as to cause the substrates in the intestines of the gastrointestinal tract to have moisture imparted thereto. 20. The method as claimed in claim 18, wherein the contacting is carried out by administering a delayed-release formulation which formulation incorporates eriodictyon fluid extract in polymer materials which are capable of preventing the release of the eriodictyon fluid extract until the eriodictyon fluid reaches the intestines.

Inventors: PARNELL FRANCIS W, PARNELL, FRANCIS, W.
Applicants: PARNELL PHARMACEUTICALS INC, PARNELL PHARMACEUTICALS, INC.
Application year: 1991
Main classification: A61K47
IPC codes: A61K9, A61K47